Ribociclib succinate - Generic Drug Details

What are the generic sources for ribociclib succinate and what is the scope of freedom to operate?

Ribociclib succinate is the generic ingredient in one branded drug marketed by Novartis and is included in one NDA. There are twelve patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ribociclib succinate has two hundred and thirty-four patent family members in fifty-four countries.

One supplier is listed for this compound.

Summary for ribociclib succinate

International Patents:	234
US Patents:	12
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	51
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ribociclib succinate
DailyMed Link:	ribociclib succinate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ribociclib succinate

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for ribociclib succinate

Drug Class	Kinase Inhibitor
Mechanism of Action	Cytochrome P450 3A Inhibitors Kinase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for ribociclib succinate

L01EF	Cyclin-dependent kinase (CDK) inhibitors
L01E	PROTEIN KINASE INHIBITORS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for RIBOCICLIB SUCCINATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
KISQALI	Tablets	ribociclib succinate	200 mg	209092	4	2021-03-15

US Patents and Regulatory Information for ribociclib succinate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	KISQALI	ribociclib succinate	TABLET;ORAL	209092-001	Mar 13, 2017		RX	Yes	Yes
Novartis	KISQALI	ribociclib succinate	TABLET;ORAL	209092-001	Mar 13, 2017		RX	Yes	Yes			Y
Novartis	KISQALI	ribociclib succinate	TABLET;ORAL	209092-001	Mar 13, 2017		RX	Yes	Yes			Y	Y
Novartis	KISQALI	ribociclib succinate	TABLET;ORAL	209092-001	Mar 13, 2017		RX	Yes	Yes
Novartis	KISQALI	ribociclib succinate	TABLET;ORAL	209092-001	Mar 13, 2017		RX	Yes	Yes
Novartis	KISQALI	ribociclib succinate	TABLET;ORAL	209092-001	Mar 13, 2017		RX	Yes	Yes
Novartis	KISQALI	ribociclib succinate	TABLET;ORAL	209092-001	Mar 13, 2017		RX	Yes	Yes

International Patents for ribociclib succinate

Country	Patent Number	Title	Estimated Expiration
Portugal	4197530
France	17C1059
Australia	2019202674	Combination therapy for the treatment of cancer
South Africa	201100994	PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS
Guatemala	201300123	SAL(ES) DE DIMETIL-AMIDA DEL ACIDO 7-CICLOPENTIL-2-(5-PIPERAZIN-1-IL-PIRIDIN-2-IL-AMINO)-7H-PIRROLO-(2,3-D)-PIRIMIDIN-6-CARBOXILICO Y PROCESOS PARA SU ELABORACION
Morocco	34653	SELS DU DIMETHYLAMIDE DE L'ACIDE 7-CYCLOPENTYL-2-(5-PIPERAZIN-1-YLPYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXYLIQUE ET LEURS PROCEDES DE FABRICATION
Japan	2019038809	７−シクロペンチル−２−（５−ピペラジン−１−イル−ピリジン−２−イルアミノ）−７Ｈ−ピロロ［２，３−Ｄ］ピリミジン−６−カルボン酸ジメチルアミドの塩およびその製造方法 (SALT(S) OF 7-CYCLOPENTYL-2-(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF)

Supplementary Protection Certificates for ribociclib succinate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2331547	17C1059	France		PRODUCT NAME: RIBOCICLIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/17/1221 20170824
2331547	201740036	Slovenia		PRODUCT NAME: RIBOCICLIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALT; NATIONAL AUTHORISATION NUMBER: EU/1/17/1221/001-012; DATE OF NATIONAL AUTHORISATION: 20170822; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2331547	2017059	Norway		PRODUCT NAME: RIBOSIKLIB ELLER ET; REG. NO/DATE: EU/1/17/1221 20170830
2331547	SPC/GB17/074	United Kingdom		PRODUCT NAME: RIBOCICLIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/17/1221/001-012 20170824; UK PLGB 00101/1100 20170824
2331547	132017000142645	Italy		PRODUCT NAME: RIBOCICLIB O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(KISQALI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1221, 20170824
2331547	LUC00048	Luxembourg		PRODUCT NAME: RIBOCICLIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/171221 20170824
2331547	664	Finland

Market Dynamics and Financial Trajectory for RIBOCICLIB SUCCINATE

Last updated: March 28, 2026

What is the current market landscape for RIBOCICLIB SUCCINATE?

Ribociclib succinate is an FDA-approved CDK4/6 inhibitor used primarily in hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. Approved in 2017 under the brand name Kisqali (by Novartis), its market penetration has been steady over the past five years.

How does Ribociclib compare to other CDK4/6 inhibitors?

Drug	Approval Year	Market Share (2022)	List Price (per month)	Key Competitors
Ribociclib	2017	35%	$11,000	Palbociclib (Ibrance), Abemaciclib (Verzenio)
Palbociclib	2015	45%	$12,300
Abemaciclib	2017	20%	$13,500

Market share is subject to regional differences. In the US, Ribociclib trails slightly behind Palbociclib but maintains a competitive position due to clinical trial performance and dosing schedules.

What is the financial trajectory based on current data?

Sales Growth

• In 2022, Kisqali generated approximately $1.37 billion globally, up from $930 million in 2020[1].
• Compound annual growth rate (CAGR) 2020–2022: approximately 22.5%.

Revenue Projections

Assuming continuation of current trends, with a 10% annual increase:

Year	Projected Revenue
2023	$1.51 billion
2024	$1.66 billion
2025	$1.83 billion

Key Risk Factors Affecting Revenue

• Patent expirations in key markets (US 2032, EU 2030).
• Competitive launches of biosimilars or generics.
• Price erosion driven by healthcare policies.

What are the pipeline developments impacting future market dynamics?

• Novartis has ongoing trials expanding use into early-stage breast cancer and other HR-positive cancers.
• Combination therapy approval with endocrine agents increases treatment breadth.
• New formulations, including once-daily dosing, aim to improve patient adherence.

How do regulatory and policy factors influence the outlook?

• US Centers for Medicare & Medicaid Services (CMS) considers value-based pricing, potentially lowering reimbursement.
• EU countries increasingly impose price caps, affecting margins.
• Patent protections and exclusivity periods will determine generics’ timing.

What is the competitive landscape and potential shifts?

• Palbociclib maintains broader market share due to earlier approval and established prescriber base.
• Abemaciclib gains market traction with potential indications for metastatic and early breast cancer.
• Biosimilars and generics are expected to enter markets starting in 2032, putting downward pressure on prices.

What strategic actions could influence financial outcomes?

• Expanding indications can unlock new revenue streams.
• Developing fixed-dose combinations with other therapies.
• Engaging in value-based pricing agreements to sustain premium pricing.

Conclusions

Ribociclib succinate's market will experience steady growth driven by clinical advantages and expanding indications. However, launching biosimilars from 2032 onward poses a significant challenge to revenue sustainability. Continuous innovation and strategic pipeline expansion will be crucial in maintaining market position.

Key Takeaways

• Ribociclib claims approximately 35% of the CDK4/6 inhibitor market based on 2022 sales.
• The global sales reach $1.37 billion, with a CAGR of roughly 22.5% from 2020 to 2022.
• Patent expiration in 2032 presents a critical inflection point for competition.
• Price pressures from healthcare policies and biosimilar entry will influence future margins.
• Expansion into new indications and combination therapies are growth opportunities.

FAQs

1. What are the main clinical advantages of Ribociclib over competitors?
   Ribociclib offers once-daily dosing and favorable safety profile, with evidence demonstrating improved progression-free survival in HR-positive breast cancer.

2. When are biosimilars expected to enter the market?
   Biosimilars for Ribociclib are anticipated starting in 2032, following patent expiration.

3. How do healthcare policies impact pricing strategies?
   Reimbursement frameworks and price caps in the US and EU exert downward pressure on drug prices, affecting revenue and profit margins.

4. Are there any new indications for Ribociclib under clinical development?
   Yes, ongoing trials explore its use in early-stage breast cancer and other hormone-driven tumors.

5. What differentiates Ribociclib from other CDK4/6 inhibitors?
   Its dosing schedule, safety profile, and clinical trial data position it as a competitive option.

---

References

[1] Novartis. (2023). Kisqali sales data and pipeline updates. Retrieved from Novartis corporate reports.

[2] IQVIA. (2023). Pharmaceutical Market Reports.